Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this clinical research trial is to study safety and effectiveness of the TransPyloric Shuttle System (TPSS) for weight reduction in patients who are considered medically obese.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TransPyloric Shuttle (TPS) | Experimental | TransPyloric Shuttle plus Lifestyle Counseling |
|
| Control | Sham Comparator | Sham procedure plus Lifestyle Counseling |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TransPyloric Shuttle | Device |
|
| |
| Sham procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group | The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline | 12 Months |
| Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL | The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50% | 12 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard I Rothstein, MD | Dartmouth Geisel School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| HonorHealth Bariatric Center | Scottsdale | Arizona | 85258 | United States | ||
| University of California San Diego |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | TransPyloric Shuttle (TPS) | TransPyloric Shuttle plus lifestyle counseling |
| FG001 | Control | Sham procedure plus lifestyle counseling. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | TransPyloric Shuttle (TPS) | TransPyloric Shuttle plus lifestyle counseling |
| BG001 | Control | Sham procedure plus lifestyle counseling. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Mean Percent Total Body Weight Loss (% TBL) Between the TPS and the Control Group | The mean percent Total Body Weight Loss (% TBL) is the percentage weight change at 12 Months from Baseline | Posted | Least Squares Mean | Standard Error | % Total Body Weight Loss | 12 Months |
|
12 months
The TPS, SAE population includes all subjects successful deliveries plus 10 subjects with attempted deliveries.
The TPS, AE population includes successful deliveries where the TPS remained for up to one year
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | TransPyloric Shuttle (TPS) | TransPyloric Shuttle plus lifestyle counseling | 0 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| esophageal rupture | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| nausea | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Lian Cunningham, MD, PhD | BAROnova, Inc | 650.638.9796 | 22 | lcunningham@baronova.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Nov 15, 2016 | Apr 20, 2019 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D015431 | Weight Loss |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Device |
|
| Lifestyle Counseling | Behavioral | The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies. |
|
| San Diego |
| California |
| 92103 |
| United States |
| University of Miami | Miami | Florida | 33166 | United States |
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | United States |
| Stony Brook Medicine | Stony Brook | New York | 11794 | United States |
| MidSouth Bariatrics | Memphis | Tennessee | 38120 | United States |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | United States |
| Baylor University Medical Center | Dallas | Texas | 75246 | United States |
| relocation, study fatigue |
|
| Pregnancy |
|
| Physician Decision |
|
| Lost to Follow-up |
|
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Units | Counts |
|---|
| Participants |
|
|
|
| Primary | Proportion of TPS-treated Subjects With Weight Loss ≥ 5% TBL | The proportion of subjects in the TPS group with ≥ 5% TBL is compared to a performance target of 50% | Per Protocol Population; received TPS Device | Posted | Count of Participants | Participants | 12 months |
|
|
|
|
| 213 |
| 10 |
| 213 |
| 203 |
| 203 |
| EG001 | Control | Sham procedure plus lifestyle counseling. | 0 | 89 | 1 | 89 | 87 | 89 |
| pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA (18.1) | Systematic Assessment | due to esophageal rupture in same patient |
|
| upper abdominal pain | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| gastric ulcer | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| vomiting | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| device intolerance | General disorders | MedDRA (18.1) | Systematic Assessment |
|
| gastric obstruction | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| cerebrovascular accident | Nervous system disorders | MedDRA (18.1) | Systematic Assessment | not device or procedure related |
|
| cholelithiasis | Hepatobiliary disorders | MedDRA (18.1) | Systematic Assessment | not device or procedure related |
|
| divericularitis | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment | not device or procedure related |
|
| meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (18.1) | Systematic Assessment | not device or procedure related |
|
| abdominal pain upper | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| vomiting | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| dyspepsia | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| diarrhea | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| abdominal distension | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| gastroesophageal reflux | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| eructation | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| constipation | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| gastritis, erosive | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| gastric mucosa erythema | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| gastric ulcer | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| abdominal pain | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| abdominal pain lower | Gastrointestinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA (18.1) | Systematic Assessment |
|
| nasopharyngitis | Infections and infestations | MedDRA (18.1) | Systematic Assessment |
|
| esophageal mucosal injury | Injury, poisoning and procedural complications | MedDRA (18.1) | Systematic Assessment | endoscopic observations during procedure |
|
| pyrexia | General disorders | MedDRA (18.1) | Systematic Assessment |
|
| pain | General disorders | MedDRA (18.1) | Systematic Assessment |
|
| headache | Nervous system disorders | MedDRA (18.1) | Systematic Assessment |
|
Not provided
Not provided
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001836 | Body Weight Changes |